Beyond Weight Loss: The Emerging Dermocosmetic Opportunity in the GLP-1 Era From pharmacological weight reduction to a new platform for skin, hair and body adaptation

The rapid adoption of glucagon-like peptide-1 receptor agonists and related incretin-based therapies hastransformed the treatment of obesity and is beginning to reshape adjacent consumer-health and aestheticmarkets. Semaglutide, tirzepatide and next-generation agents can produce degrees of weight reduction thatwere previously uncommon outside metabolic surgery. That therapeutic success can be accompanied by asecond, increasingly visible set of aesthetic and integumentary needs: facial soft-tissue deflation, accentuationof pre-existing laxity and folds, changes in body contour, and hair shedding. These phenomena should not bereduced to the popular but scientifically imprecise label ‘Ozempic face’. In many patients, the dominantdrivers are likely to include the magnitude and velocity of weight loss, loss of subcutaneous support, age-dependent limits in tissue recoil, changes in body composition, lower total food intake and pre-existingphotoageing. At the same time, emerging mechanistic literature suggests that GLP-1 signalling in skin iscomplex and may include potentially favourable anti-inflammatory and regenerative effects. The result is nota simple toxicity narrative but a new problem of tissue adaptation during metabolic transformation. Thisreview proposes an independent, evidence-led category: a GLP-1-era dermocosmetic adaptation platformintegrating topical facial and body care, scalp and hair care, selected nutricosmetic support, professionalaesthetic pathways and prospective clinical validation. The commercial opportunity is potentially significantbecause it is attached not to one pharmaceutical brand, but to the structural expansion of pharmacologicalobesity management. Its long-term credibility, however, will depend on disciplined claims, objectiveendpoints and a clear understanding of what cosmetics can — and cannot — achieve.